At a glance

ClinicalIndex Comparison Record

Phase 3Completed· 221 enrolled

Drug / intervention

HDC +1 moredrug

Likely dose

Not stated in record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01049373

NCT01049373Phase 3Completed

Compare CT.gov

Efficacy and Safety of Lymphdiaral Basistropfen (a Fixed Homoeopathic Remedy [HDC]) in the Treatment of Chronic Low-back Pain Considering Constitution and Diathesism: a Double Blind, Randomised, Placebo Controlled, Single-centre Study

Pascoe Pharmazeutische Praeparate GmbH·interventional·Posted Jan 14, 2010·Updated Sep 6, 2012

In Brief

A Phase 3 clinical trial evaluating HDC and Placebo solution for Low Back Pain. Completed, enrolled 221 participants across 1 site.

Detailed Summary

To evaluate superiority of HDC in comparison to placebo in the treatment of chronic low-back pain in relation to pain, functional impairment, quality of life, and state of health during a 15-week treatment period.

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsLow Back Pain

CountriesGermany

Collaborators--

Timeline

Phase 3CompletedFinished

200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027

Enrollment StartDec 2003

Primary CompletionMay 2007

First PostedJan 2010

TodayJul 2026

First PostedJan 14, 2010

Enrollment StartDec 1, 2003

Primary CompletionMay 1, 2007

TodayJul 2, 2026

Enrollment to primary: 3.4 yearsPosted 16.5 years ago

Interventions

HDCdrug

(Calendula mother tincture, Condurango 2X, Phytolacca 2X, Carduus marianus 1X, Chelidonium 2X, Hydrastis mother tincture, Leptandra mother tincture, Taraxacum mother tincture, Echinacea mother tincture, Lycopodium 2X, Sanguinaria mother tincture and Arsenicum album 8X),10 drops t.i.d. for 15 weeks.

Placebo solutiondrug

10 drops, t.i.d, 15 weeks